公开(公告)号：US20240366567A1

公开(公告)日：2024-11-07

申请号：US18572518

申请日：2022-06-23

Applicant: NOVARTIS AG

Inventor： Saskia Maria BRACHMANN ,  Simona COTESTA ,  Xiaoming CUI ,  Ruben DE KANTER ,  Anna FARAGO ,  Marc GERSPACHER ,  Diana GRAUS PORTA ,  Jaeyeon KIM ,  Catherine LEBLANC ,  Edwige Liliane Jeanne LORTHIOIS ,  Rainer MACHAUER ,  Robert MAH ,  Christophe MURA ,  Pascal RIGOLLIER ,  Anirudh Cadapa PRAHALLAD ,  Nadine SCHNEIDER ,  Rowan STRINGER ,  Stefan STUTZ ,  Andrea VAUPEL ,  Nicolas WARIN ,  Rainer WILCKEN ,  Andreas WEISS

IPC: A61K31/416 ,  A61K31/519 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/22

Abstract: The present invention relates to a pharmaceutical combination comprising a KRAS G12C inhibitor and one or more therapeutic agents which is selected from an agent targeting the MARK pathway or an agent targeting parallel pathways; and pharmaceutical compositions comprising the same. The invention also relates to KRAS G12C inhibitors alone or said combinations for use in methods of treating a cancer or a tumor, in particular wherein the cancer or tumor is KRAS G12C mutant.